Back to Search Start Over

Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases.

Authors :
Garcia-Pavia P
Rapezzi C
Adler Y
Arad M
Basso C
Brucato A
Burazor I
Caforio ALP
Damy T
Eriksson U
Fontana M
Gillmore JD
Gonzalez-Lopez E
Grogan M
Heymans S
Imazio M
Kindermann I
Kristen AV
Maurer MS
Merlini G
Pantazis A
Pankuweit S
Rigopoulos AG
Linhart A
Source :
European journal of heart failure [Eur J Heart Fail] 2021 Apr; Vol. 23 (4), pp. 512-526. Date of Electronic Publication: 2021 Apr 07.
Publication Year :
2021

Abstract

Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the hereditary forms or as a consequence of acquired conditions. Thanks to advances in imaging techniques and the possibility of achieving a non-invasive diagnosis, we now know that cardiac amyloidosis is a more frequent disease than traditionally considered. In this position paper the Working Group on Myocardial and Pericardial Disease proposes an invasive and non-invasive definition of cardiac amyloidosis, addresses clinical scenarios and situations to suspect the condition and proposes a diagnostic algorithm to aid diagnosis. Furthermore, we also review how to monitor and treat cardiac amyloidosis, in an attempt to bridge the gap between the latest advances in the field and clinical practice.<br /> (© European Society of Cardiology 2021.)

Details

Language :
English
ISSN :
1879-0844
Volume :
23
Issue :
4
Database :
MEDLINE
Journal :
European journal of heart failure
Publication Type :
Academic Journal
Accession number :
33826207
Full Text :
https://doi.org/10.1002/ejhf.2140